Therapy News and Research

RSS

AltheRx reports positive Phase II results of Solabegron for OAB

AltheRx Pharmaceuticals, a privately-held clinical development company, presented positive results from its Phase II study of Solabegron in overactive bladder (OAB) at the American Urological Association Annual Meeting (Abstract # 520).

21 May 2012

$Anti-clotting drugs rarely needed in children with big-bone fractures$

Anti-clotting drugs rarely needed in children with big-bone fractures

Children with pelvic and thigh fractures develop dangerous blood clots so rarely that anti-clotting therapy should be given only to those with underlying conditions that increase clotting risk, according to a study from Johns Hopkins Children’s Center.

21 May 2012

Growth promoting substance in human mesenchymal stem cells spurs restoration of nerves

A substance in human mesenchymal stem cells that promotes growth appears to spur restoration of nerves and their function in rodent models of multiple sclerosis (MS), researchers at Case Western Reserve University School of Medicine have found.

21 May 2012

Biomarker neutralizes effect of bevacizumab in pancreas and kidney cancer patients

Diether Lambrechts (VIB - KU Leuven) said "in two large clinical studies with patients with advanced stages of pancreas and kidney cancer a variant in the DNA was discovered that identified patients who did not respond well to the prescribed course of bevacizumab.

21 May 2012

Pernix Therapeutics introduces Omeclamox-Pak® for the treatment of H. pylori infection and duodenal ulcer disease

Pernix Therapeutics Holdings, Inc. (NYSE Amex: PTX), a specialty pharmaceutical company, today announced the introduction of Omeclamox-Pak®, a ten-day therapy of omeprazole delayed-release capsules (20 mg), clarithromycin tablets (500 mg) and amoxicillin capsules (500 mg) for the treatment of Helicobacter pylori (H. pylori) infection and duodenal ulcer disease (active or one-year history) to eradicate H. pylori in adult patients.

21 May 2012

Vaccination studies from Mercer University to be unveiled at AAPS’ NBC

Vaccination studies from Mercer University (Ga.) headline the groundbreaking research being unveiled at the American Association of Pharmaceutical Scientists' (AAPS) National Biotechnology Conference.

21 May 2012

RA drug effective against Entamoeba histolytica

Research by a collaborative group of scientists from UC San Diego School of Medicine, UC San Francisco and Wake Forest School of Medicine has led to identification of an existing drug that is effective against Entamoeba histolytica. This parasite causes amebic dysentery and liver abscesses and results in the death of more than 70,000 people worldwide each year.

21 May 2012

Experimental bariatric surgery can lower blood sugar levels in rats with type 1 diabetes

For the first time, scientists at the Toronto General Hospital Research Institute have shown that an experimental bariatric surgery can lower blood sugar levels in rats with type 1 diabetes.

21 May 2012

Hypertonic saline does not reduce rate of pulmonary exacerbations in young children with CF

Margaret Rosenfeld, M.D., M.P.H., of Seattle Children's Hospital, and colleagues conducted a study to examine if hypertonic saline would reduce the rate of pulmonary exacerbations in children younger than 6 years of age with cystic fibrosis.

21 May 2012

Auranofin effective against amoebas in lab and animal studies

A team of researchers from UCSF and UC San Diego has identified an approved arthritis drug that is effective against amoebas in lab and animal studies, suggesting it could offer a low-dose, low cost treatment for the amoebic infections that cause human dysentery throughout the world.

21 May 2012

Treatment of early stage prostate cancer can also result in improved QOL for men with LUTS

Treatment of early stage prostate cancer can also result in improved quality of life for a subgroup of men who suffer from lower urinary tract symptoms (LUTS), according to an abstract of a Beth Israel Deaconess Medical Center-led study presented to the American Urological Association.

21 May 2012

Statin therapy prevents cancer and reduces death risk in heart transplant recipients

Statins prevent cancer and reduce death from all causes in heart transplant recipients. The findings were independent of cholesterol levels.

21 May 2012

Study identifies biomarkers that predict patients' response to certain colon cancer drugs

The Stem Cells and Cancer Research Group headed by Dr H-ctor G. Palmer at the Vall d'Hebr-n Institute of Oncology (VHIO) has identified the molecular mechanisms that determine patients' response to certain drugs used in clinical trials for colon cancer treatment. The study led by VHIO also benefited from the collaboration with Professor Alberto Mu-oz-s laboratory at the Instituto de Investigaciones Biomedicas Alberto Sols, Consejo Superior de Investigaciones Cient-ficas.

21 May 2012

Panobinostat able to target and destroy triple negative breast cancer

The histone de-acetylase (HDAC) inhibitor panobinostat is able to target and destroy triple negative breast cancer, reveals a new study published in BioMed Central's open access journal Breast Cancer Research.

21 May 2012

POZEN presents data from PA32540 Phase 1 gastric acid reduction study at DDW 2012

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, presented data today from a Phase 1 study that found that the investigational compound, PA32540, provides faster protection compared with delayed-release, enteric-coated omeprazole (40 mg), as measured by mean time to gastric pH.

21 May 2012

Ceregene announces new data from CERE-120 clinical trial on Parkinson's

Ceregene Inc., a biotechnology company developing treatments for neurodegenerative diseases such as Parkinson's disease, will present new data demonstrating long-term, biologically-active expression of neurturin, a nervous system growth factor delivered to the degenerating dopamine nerves in patients with Parkinson's disease following treatment with CERE-120.

19 May 2012

Final results from C3BS-CQR-1 Phase II trial on heart failure

The Belgian biotechnology company, Cardio3 BioSciences (C3BS), a leader in the discovery and development of regenerative and protective therapies for the treatment of cardiovascular diseases, today announces that the final results of its Phase II clinical trial of C3BS-CQR-1 is will be presented at the late breaking clinical trial session at the European Society of Cardiology 2012 Heart Failure Congress in Belgrade, Serbia taking place on May 19-22.

19 May 2012

Positive results from CardioKinetix Parachute system study on heart failure

CardioKinetix Inc., a medical device company pioneering a catheter-based treatment for heart failure, today announced two-year clinical results for the first-of-its-kind catheter-based Parachute Ventricular Partitioning Device, a Percutaneous Ventricular Restoration (PVR) therapy for patients with ischemic heart failure.

19 May 2012

AACN to honor Detroit nurse with Flame of Excellence Award

The American Association of Critical-Care Nurses (AACN) will present the Flame of Excellence Award to Margaret L. "Meg" Campbell, Ph.D., RN, FAAN, a nationally known expert in hospital-based palliative care and end-of-life issues.

19 May 2012

Mount Sinai cancer researchers to present several landmark studies at ASCO meeting

Mount Sinai School of Medicine researchers will present several landmark studies, including data on treatment trends in late-stage cancer, a promising multiple myeloma vaccine, and predictive models of soft tissue sarcomas, prostate and bladder cancer, at the 2012 American Society of Clinical Oncology (ASCO) meeting June 1-5, 2012 in Chicago.

19 May 2012

Therapy News and Research

AltheRx reports positive Phase II results of Solabegron for OAB

Anti-clotting drugs rarely needed in children with big-bone fractures

Growth promoting substance in human mesenchymal stem cells spurs restoration of nerves

Biomarker neutralizes effect of bevacizumab in pancreas and kidney cancer patients

Pernix Therapeutics introduces Omeclamox-Pak® for the treatment of H. pylori infection and duodenal ulcer disease

Vaccination studies from Mercer University to be unveiled at AAPS’ NBC

RA drug effective against Entamoeba histolytica

Experimental bariatric surgery can lower blood sugar levels in rats with type 1 diabetes

Hypertonic saline does not reduce rate of pulmonary exacerbations in young children with CF

Auranofin effective against amoebas in lab and animal studies

Treatment of early stage prostate cancer can also result in improved QOL for men with LUTS

Statin therapy prevents cancer and reduces death risk in heart transplant recipients

Study identifies biomarkers that predict patients' response to certain colon cancer drugs

Panobinostat able to target and destroy triple negative breast cancer

POZEN presents data from PA32540 Phase 1 gastric acid reduction study at DDW 2012

Ceregene announces new data from CERE-120 clinical trial on Parkinson's

Final results from C3BS-CQR-1 Phase II trial on heart failure

Positive results from CardioKinetix Parachute system study on heart failure

AACN to honor Detroit nurse with Flame of Excellence Award

Mount Sinai cancer researchers to present several landmark studies at ASCO meeting

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News